

Sanierung von MRSA-positiven Patienten

Nils-Olaf Hübner, Kathrin Wander, Sylvia Ryll und Axel Kramer, Greifswald

Arzneimitteltherapie 2009;27:x-y.

Literatur

- Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant *Staphylococcus aureus* (MRSA). *Int J Antimicrob Agents* 2007;30:398.
- Back NA, Linnemann CC Jr., Staneck JL, Kotagal UR. Control of methicillin-resistant *Staphylococcus aureus* in a neonatal intensive-care unit: use of intensive microbiologic surveillance and mupirocin. *Infect Control Hosp Epidemiol* 1996;17:227–31.
- Baddour MM, Abuelkheir MM, Fatani AJ. Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia. *Ann Clin Microbiol Antimicrob* 2006;5:30.
- Baptiste KE, Williams K, Willams NJ, Wattret A, et al. Methicillin-resistant staphylococci in companion animals. *Emerg Infect Dis* 2005;11:1942–4.
- Batra R, Eziefula AC, Wyncoll D, Edgeworth J. Throat and rectal swabs may have an important role in MRSA screening of critically ill patients. *Intensive Care Med* 2008;34:1703–6.
- Bertin ML, Vinski J, Schmitt S, Sabella C, et al. Outbreak of methicillin-resistant *Staphylococcus aureus* colonization and infection in a neonatal intensive care unit epidemiologically linked to a healthcare worker with chronic otitis. *Infect Control Hosp Epidemiol* 2006;27:581–5.
- Block C, Robenshtok E, Simhon A, Shapiro M. Evaluation of chlorhexidine and povidone iodine activity against methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant *Enterococcus faecalis* using a surface test. *J Hosp Inf* 2000;46:147–52.
- Bloomfield SF, Cookson B, Falkiner F, Griffith C, et al. Methicillin-resistant *Staphylococcus aureus*, *Clostridium difficile*, and extended-spectrum beta-lactamase-producing *Escherichia coli* in the community: assessing the problem and controlling the spread. *Am J Infect Control* 2007;35:86–8.
- Boelaert JR, De Baere YA, Geernaert MA, Godard CA, et al. The use of nasal mupirocin ointment to prevent *Staphylococcus aureus* bacteremias in haemodialysis patients: an analysis of cost-effectiveness. *J Hosp Infect* 1991;19(Suppl B):41–6.
- Boyce JM, Havill NL, Maria B. Frequency and possible infection control implications of gastrointestinal colonization with methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 2005;43:5992–5.
- Brady A, Loughlin R, Gilpin D, Kearney P, et al. In vitro activity of tea-tree oil against clinical skin isolates of methicillin-resistant and -sensitive *Staphylococcus aureus* and coagulase-negative staphylococci growing planktonically and as biofilms. *J Med Microbiol* 2006;55:1375.
- Buehlmann M, Frei R, Fenner L, Dangel M, et al. Highly effective regimen for decolonization of methicillin-resistant *Staphylococcus aureus* carriers. *Infect Control Hosp Epidemiol* 2008;29:510.
- Casewell MW. New threats to the control of methicillin-resistant *Staphylococcus aureus*. *J Hosp Infect* 1995;30(Suppl):465–71.
- Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. *J Antimicrob Chemother* 1998;41:11–8.
- Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* bacteremia: a meta-analysis. *Clin Infect Dis* 2003;36:53.
- Cotterill S, Evans R, Fraise AP. An unusual source for an outbreak of methicillin-resistant *Staphylococcus aureus* on an intensive therapy unit. *J Hosp Infect* 1996;32:207–16.
- Cutler RR, Wilson P. Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant *Staphylococcus aureus*. *Br J Biomed Sci* 2004;61:71.
- Dall'Antonia M, Coen PG, Wilks M, Whiley A, et al. Competition between methicillin-sensitive and -resistant *Staphylococcus aureus* in the anterior nares. *J Hosp Infect* 2005;61:62.
- Dancer SJ. Importance of the environment in methicillin-resistant *Staphylococcus aureus* acquisition: the case for hospital cleaning. *Lancet Infect Dis* 2008;8:101–13.
- Davies EA, Emmerson AM, Hogg GM, Patterson MF, et al. An outbreak of infection with a methicillin-resistant *Staphylococcus aureus* in a special care baby unit: value of topical mupirocin and of traditional methods of infection control. *J Hosp Infect* 1987;10:120–8.
- Davis KA, Stewart JJ, Crouch HK, Florez CE, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. *Clin Infect Dis* 2004;39:776–82.
- Dembl T, Obrdzlek V, Votava M. Inhibition of bacterial pathogens by lactobacilli. *Zentralbl Bakteriologie: Int J Med Microbiol* 1998;288:395.
- Falagas ME, Vardakas KZ. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. *Drug Saf* 2008;31:753.
- Fernandez C, Gaspar C, Torrellas A, Vindel A, et al. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of *Staphylococcus aureus* among hospital personnel. *J Antimicrob Chemother* 1995;35:399–408.
- Flaxman D, Griffiths P. Is tea tree oil effective at eradicating MRSA colonization? A review. *Br J Community Nurs* 2005;10:123.
- Goetz MB, Mulligan ME, Kwok R, O'Brien H, et al. Management and epidemiologic analyses of an outbreak due to methicillin-resistant *Staphylococcus aureus*. *Am J Med* 1992;92:607–14.
- Goodman ER, Platt R, Bass R, Onderdonk AB, et al. Impact of an environmental cleaning intervention on the presence of methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci on surfaces in intensive care unit rooms. *Infect Control Hosp Epidemiol* 2008;29:593–9.
- Gopal Rao G, Wong J. Interaction between methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-sensitive *Staphylococcus aureus* (MSSA). *J Hosp Infect* 2003;55:116.
- Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant *Staphylococcus aureus* as a public-health threat. *Lancet* 2006;368:874–5.
- Guilhermetti M, Hernandez SE, Fukushigie Y, Garcia LB, et al. Effectiveness of hand-cleansing agents for removing methicillin-resistant *Staphylococcus aureus* from contaminated hands. *Infect Control Hosp Epidemiol* 2001;22:105–8.
- Haddad Q, Sobayo EI, Basit OB, Rotimi VO. Outbreak of methicillin-resistant *Staphylococcus aureus* in a neonatal intensive care unit. *J Hosp Infect* 1993;23:211–22.
- Hansen D, Patzke PI, Werfel U, Benner D, et al. Success of MRSA eradication in hospital routine: depends on compliance. *Infection* 2007;35:260.
- Harbarth S, Liassine N, Herrault P, Auckenthaler R, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant. *Microbiology* 1999;43:1412–6.

Dr. med. Nils-Olaf Hübner, Sylvia Ryll, Prof. Dr. med. Axel Kramer, Institut für Hygiene und Umweltmedizin, Ernst-Moritz-Arndt-Universität, Walter-Rathenau-Straße 49a, 17489 Greifswald, E-Mail: nhuebner@uni-greifswald.de
Kathrin Wander, Universitätsklinikum Greifswald, Universitätsapotheke, Jahnstr. 20, 17489 Greifswald

34. Harbarth S, Dharan S, Liassine N, Herrault P, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1999;43:1412.
35. Hardy KJ, Oppenheim BA, Gossain S, Gao F, et al. A study of the relationship between environmental contamination with methicillin-resistant *Staphylococcus aureus* (MRSA) and patients' acquisition of MRSA. *Infect Control Hosp Epidemiol* 2006;27:127–32.
36. Hitomi S, Kubota M, Mori N, Baba S, et al. Control of a methicillin-resistant *Staphylococcus aureus* outbreak in a neonatal intensive care unit by unselective use of nasal mupirocin ointment. *J Hosp Infect* 2000;46:123–9.
37. Huang Y, Oie S, Kamiya A. Comparative effectiveness of hand-cleansing agents for removing methicillin-resistant *Staphylococcus aureus* from experimentally contaminated fingertips. *Am J Infect Control* 1994;22:224–7.
38. Hübner N, Kramer A. Antibiotikaresistenz bei *Staphylococcus aureus* – Implikationen für ambulantes Operieren. *Ambulante Chirurgie* 2008;12:30–3.
39. Hübner N, Kramer A, Dölken S, Bruns R. MRSA – Sanierung von Neonaten – eine therapeutische Herausforderung. 16. Jahrestagung der Deutschen Gesellschaft für pädiatrische Infektiologie, Erlangen, 2008.
40. Hudson IR. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. *J Hosp Infect* 1994;27:81–98.
41. James L, Gorwitz RJ, Jones RC, Watson JT, et al. Methicillin-resistant *Staphylococcus aureus* infections among healthy full-term newborns. *Arch Dis Child Fetal Neonatal Ed* 2008;93:F40–4.
42. Johnson AP. Antibiotic resistance among clinically important gram-positive bacteria in the UK. *J Hosp Infect* 1998;40:17–26.
43. Jones RN. Key considerations in the treatment of complicated staphylococcal infections. *Clin Microbiol Infect* 2008;14(Suppl 2):3.
44. Kampf G. The value of using chlorhexidine soap in a controlled trial to eradicate MRSA in colonized patients. *J Hosp Infect* 2004;58:86.
45. Kampf G, Jarosch R, Rüden H. Limited effectiveness of chlorhexidine based hand disinfectants against methicillin-resistant *Staphylococcus aureus* (MRSA). *J Hosp Infect* 1998;38:297.
46. Kanamori Y, Hashizume K, Kitano Y, Tanaka Y, et al. Anaerobic dominant flora was reconstructed by synbiotics in an infant with MRSA enteritis. *Pediatr Int* 2003;45:359.
47. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev* 1997;10:505–20.
48. Kniehl E, Becker A, Forster DH. Bed, bath and beyond: pitfalls in prompt eradication of methicillin-resistant *Staphylococcus aureus* carrier status in healthcare workers. *J Hosp Infect* 2005;59:180–7.
49. Kramer A, Hübner N, Zygmunt M. Greifswalder Präventionsstrategie greift. *Dtsch Hebammen Z* 2008;26–8.
50. Kramer A, Reichwagen S, Widulle H, Heldt P. N-Heterocyclen. In: Kramer A, Assadian O (Hrsg.). *Wahlhäufers Praxis der Sterilisation, Desinfektion, Antiseptik und Konservierung*. 6. Auflage. Stuttgart: Thieme, 2008:799–812.
51. Kramer A, Reichwagen S, Widulle H, Heldt P. Guanidine und Biguanide. In: Kramer A, Assadian O (Hrsg.). *Wahlhäufers Praxis der Sterilisation, Desinfektion, Antiseptik und Konservierung*. 6. Auflage. Stuttgart: Thieme, 2008:788–99.
52. Kresken M, Hafner D, Schmitz F, Wichelhaus T (editors). Prevalence of mupirocin resistance in isolates of *Staphylococcus aureus* and *Staphylococcus epidermidis* in three Central European countries: Results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy 2001. 13th ECCMID, Glasgow/UK, 2003:Poster No 1448.
53. Lepelletier D. Methicillin-resistant *Staphylococcus aureus*: incidence, risk factors and interest of systematic screening for colonization in intensive-care unit. *Ann Fr Anesth Reanim* 2006;25:626–32.
54. Levine DP. Vancomycin: understanding its past and preserving its future. *South Med J* 2008;101:284.
55. Loeffler A, Boag AK, Sung J, Lindsay JA, et al. Prevalence of methicillin-resistant *Staphylococcus aureus* among staff and pets in a small animal referral hospital in the UK. *J Antimicrob Chemother* 2005;56:692.
56. Lukowski G, Lindequist U, Mundt S, Kramer A, et al. Inhibition of dermal MRSA colonization by microalgal micro- and nanoparticles. *Skin Pharmacol Physiol* 2008;21:98–105.
57. Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. *Med J Aust* 2007;186:454.
58. McMahon MAS, Blair IS, McDowell DA. Habituation to sub-lethal concentrations of tea tree oil (*Melaleuca alternifolia*) is associated with reduced susceptibility to antibiotics in human pathogens. *J Antimicrob Chemother* 2007;59:125.
59. McMahon MAS, Tunney MM, Moore JE, Blair IS, et al. Changes in antibiotic susceptibility in staphylococci habituated to sub-lethal concentrations of tea tree oil (*Melaleuca alternifolia*). *Lett Appl Microbiol* 2008;47:263.
60. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant *Staphylococcus aureus* after widespread use of nasal mupirocin ointment. *Infect Control Hosp Epidemiol* 1996;17:811–3.
61. Neely AN, Maley MP. Survival of enterococci and staphylococci on hospital fabrics and plastic. *J Clin Microbiol* 2000;38:724–6.
62. Neely AN, Sittig DF. Basic microbiologic and infection control information to reduce the potential transmission of pathogens to patients via computer hardware. *J Am Med Inform Assoc* 2002;9:500–8.
63. Niclaes L, Buntinx F, Banuro F, Lesaffre E, et al. Consequences of MRSA carriage in nursing home residents. *Epidemiol Infect* 1999;122:235–9.
64. Otero MaC, Nader-Macías MaE. Inhibition of *Staphylococcus aureus* by H2O2-producing *Lactobacillus gasseri* isolated from the vaginal tract of cattle. *Anim Reprod Sci* 2006;96:35.
65. Pappa KA. The clinical development of mupirocin. *J Am Acad Dermatol* 1990;22:873–9.
66. Park H, Jang C-H, Cho YB, Choi C-H. Antibacterial effect of tea-tree oil on methicillin-resistant *Staphylococcus aureus* biofilm formation of the tympanostomy tube: an in vitro study. *In Vivo* 2007;21:1027–30.
67. Rebscher H. MRSA und die gesundheitsökonomischen Folgen. Berlin: Hauptstadt kongress, 2008.
68. Ridenour G, Lampen R, Federspiel J, Kritchevsky S, et al. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant *Staphylococcus aureus* colonization and infection among intensive care unit patients. *Infect Control Hosp Epidemiol* 2007;28:1155.
69. Rohr U. Methicillin-resistant *Staphylococcus aureus* whole-body decolonization among hospitalized patients with variable site colonization by using mupirocin in combination with octenidine dihydrochloride. *J Hosp Infect* 2003;54:305–9.
70. Rohr U, Mueller C, Wilhelm M, Muhr G, et al. Methicillin-resistant *Staphylococcus aureus* whole-body decolonization among hospitalized patients with variable site colonization by using mupirocin in combination with octenidine dihydrochloride. *J Hosp Infect* 2003;54:305–9.
71. Safdar N, Bradley EA. The risk of infection after nasal colonization with *Staphylococcus aureus*. *Am J Med* 2008;121:310–5.
72. Scott E, Duty S, Callahan M. A pilot study to isolate *Staphylococcus aureus* and methicillin-resistant *S. aureus* from environmental surfaces in the home. *Am J Infect Control* 2008;36:458.
73. Semret M, Miller MA. Topical mupirocin for eradication of MRSA colonization with mupirocin-resistant strains. *Infect Control Hosp Epidemiol* 2001;22:578–80.
74. Sherertz RJ, Bassetti S, Bassetti-Wyss B. “Cloud” health-care workers. *Emerg Infect Dis* 2001;7:241–4.
75. Shiojima T, Ohki Y, Nako Y, Morikawa A, et al. Immediate control of a methicillin-resistant *Staphylococcus aureus* outbreak in a neonatal intensive care unit. *J Infect Chemother* 2003;9:243–7.
76. Shopsin B, Mathema B, Zhao X, Martinez J, et al. Resistance rather than virulence selects for the clonal spread of methicillin-resistant *Staphylococcus aureus*: implications for MRSA transmission. *Microb Drug Resist* 2000;6:239–44.
77. Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant *Staphylococcus aureus* prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. *Crit Care Med* 2006;34:700.
78. Simor AE, Phillips E, McGeer A, Konvalinka A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant *Staphylococcus aureus* colonization. *Clin Infect Dis* 2007;44:178.
79. Sloat N, Siebert J, Hoffler U. Eradication of MRSA from carriers by means of whole-body washing with an antiseptic in combination with mupirocin nasal ointment. *Zentralbl Hyg Umweltmed* 1999;202:513–23.
80. Takahashi S, Minami K, Ogawa M, Miyamoto H, et al. The preventive effects of mupirocin against nasotracheal intubation-related bacterial carriage. *Anesth Analg* 2003;97:222–5.
81. Thomas DG, Wilson JM, Day MJ, Russell AD. Mupirocin resistance in staphylococci: development and transfer of isoleucyl-tRNA synthetase-mediated resistance in vitro. *J Appl Microbiol* 1999;86:715–22.
82. Tsao S-M, Liu W-H, Yin M-C. Two daily sulphides derived from garlic inhibit methicillin-resistant *Staphylococcus aureus* infection in diabetic mice. *J Med Microbiol* 2007;56:803.
83. Vandenesch F, Etienne J. How to prevent transmission of MRSA in the open community? *Euro Surveill* 2004;9:5.

84. Voravuthikunchai SP, Bilaso S, Supamala O. Antagonistic activity against pathogenic bacteria by human vaginal lactobacilli. *Anaerobe* 2006;12:221–6.
85. Voss A, Bradley N, Doebbeling BN. The worldwide prevalence of methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents* 1995;5:101–6.
86. Wagenvoort JHT, De Brauwier EIGB, Sijstermans MLH, Toenbreker HMJ. Risk of re-introduction of methicillin-resistant *Staphylococcus aureus* into the hospital by intrafamilial spread from and to healthcare workers. *J Hosp Infect* 2005;59:67.
87. Wang JT, Sheng WH, Wang JL, Chen D, et al. Longitudinal analysis of chlorhexidine susceptibilities of nosocomial methicillin-resistant *Staphylococcus aureus* isolates at a teaching hospital in Taiwan. *J Antimicrob Chemother* 2008;62:514–7.
88. Watanakunakorn C, Axelson C, Bota B, Stahl C. Mupirocin ointment with and without chlorhexidine baths in the eradication of *Staphylococcus aureus* nasal carriage in nursing home residents. *Am J Infect Control* 1995;23:306.
89. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers. *Cochrane Database Syst Rev*. 2008:CD006216.
90. Weese JS, Dick H, Willey BM, McGeer A, et al. Suspected transmission of methicillin-resistant *Staphylococcus aureus* between domestic pets and humans in veterinary clinics and in the household. *Vet Microbiol* 2006;115:148.
91. Wendt C, Schinke S, Württemberger M, Oberdorfer K, et al. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant *Staphylococcus aureus*: a randomized, placebo-controlled, double-blind clinical trial. *Infect Control Hosp Epidemiol* 2007;28:1036.
92. Wenzel RP. Healthcare workers and the incidence of nosocomial infection: can treatment of one influence the other? – a brief review. *J Chemother* 1994;6(Suppl 4):33–7; discussion 39–40.
93. Wertheim HF, van Kleef M, Vos MC, Ott A, et al. Nose picking and nasal carriage of *Staphylococcus aureus*. *Infect Control Hosp Epidemiol* 2006;27:863–7.
94. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, et al. The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect Dis* 2005;5:751–62.
95. Zastrow K, Kramer A. Therapeutic indications for local anti-infectives. Recommendations for isolation and antiseptic sanitation of patients with MRSA colonization or infection. *Dev Ophthalmol* 2002;33:250–62.